Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1/rhIGFBP-3 continuous infusion in very preterm infants for prevention of retinopathy of prematurity
NL-OMON42210Phase 2Active, not recruiting
- Sponsor
- MediServ
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mecasermin rinfabate in retinopathy of prematurity (ROP) (2 arms), sponsored by MediServ. Primary endpoints: Severity of retinopathy of prematurity, Dose confirmation for physiologic IGF-1 exposure and 2 more. Started Mar 2015; status: active, not recruiting.
02
Drugs
mecasermin rinfabate
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NL-OMON42210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42210.